NICE Recommends GSK’s Blenrep for Multiple Myeloma Treatment in England

The National Institute for Health and Care Excellence (NICE) has recommended the use of GSK's Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) as a second-line treatment for multiple myeloma (MM) in adults refractory to or intolerant of lenalidomide. This recommendation, made public on June 13, 2025, marks a significant milestone in cancer treatment, as it allows eligible patients in England to be the first globally to access this innovative therapy.

Multiple myeloma is a form of blood cancer that arises from plasma cells in the bone marrow. Each year, approximately 6,240 cases are diagnosed in the UK, with a significant percentage of patients—estimated at 64%—requiring second-line therapies due to relapses or resistance to initial treatments. The introduction of Blenrep, administered via infusion, represents a novel approach, specifically targeting the B-cell maturation antigen (BCMA) protein prevalent on MM cells.

NICE’s endorsement follows the approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and is supported by promising data from the Phase 3 DREAMM-7 study. The study revealed that after one year of treatment, 71% of patients receiving the Blenrep combination remained free from disease progression, a notable improvement compared to 51% in the standard care group. Moreover, the three-year survival rate was reported at 74% for the Blenrep group, versus 60% for those on conventional treatment.

Peter Johnson, NHS England's national clinical director for cancer, expressed enthusiasm regarding the development. He stated, “I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.”

Antoine Herbaux, Vice President and Head of Oncology UK at GSK, commended NICE’s decision, underscoring the significance of UK innovation in the development of this drug. He noted that Blenrep was partially discovered in GSK's laboratories in Stevenage, emphasizing the pride associated with making this treatment available to local patients.

The implications of NICE’s recommendation extend beyond immediate patient access; they highlight the ongoing evolution in the treatment landscape for multiple myeloma. This development may encourage further research into similar therapies and enhance the standard of care for patients facing this challenging diagnosis. As the medical community observes the outcomes from the Blenrep treatment, it remains crucial to assess both the economic and social impacts of introducing such innovative therapies into mainstream healthcare.

Additionally, the global context of this decision illustrates the UK's commitment to pioneering advancements in cancer treatment, potentially influencing other countries to consider similar pathways for expedited patient access to groundbreaking therapies. As more data emerges from ongoing trials, the healthcare system and stakeholders must work collaboratively to ensure that patients receive the full benefits of these innovations while monitoring their effectiveness and safety in broader populations.